Literature DB >> 8521303

Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis.

P M Kessler1, S P Vasavada, R R Rackley, T Stackhouse, F M Duh, F Latif, M I Lerman, B Zbar, B R Williams.   

Abstract

BACKGROUND: Von Hippel-Lindau (VHL) disease is a familial cancer syndrome that has a dominant inherited pattern which predisposes affected individuals to a variety of tumours. The most frequent tumors are hemangioblastomas of the central nervous system and retina, renal cell carcinoma (RCC), and pheochromocytoma. The recent identification and characterization of the VHL gene on human chromosome 3p and mutational analyses confirms the VHL gene functions as a classical tumor suppressor. Not only are mutations in this gene responsible for the VHL syndrome, but mutations are also very frequent in sporadic RCC.
MATERIALS AND METHODS: VHL expression in human kidney and during embryogenesis, was analyzed by in situ mRNA hybridization with 35S-labeled antisense VHL probes, derived from human and mouse cDNAs, on cryosections of human fetal kidney and paraffin sections of murine embryos.
RESULTS: In human fetal kidney, there was enhanced expression of VHL within the epithelial lining of the proximal tubules. During embryogenesis, VHL expression was ubiquitous in all three germ cell layers and their derivatives. Expression occurred in the cerebral cortex, midbrain, cerebellum, retina, spinal cord, and postganglionic cell bodies. All organs of the thoracic and abdominal cavities expressed VHL, but enhanced expression was most apparent in the epithelial components of the lung, kidney, and eye.
CONCLUSIONS: In human fetal kidney, the enhanced epithelial expression of the VHL gene is consistent with the role of this gene in RCC. There is widespread expression of the VHL gene during embryogenesis, but this is pronounced in areas associated with VHL phenotypes. These findings provide a histological framework for investigating the physiological role of the VHL gene and as basis for further mutational analysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521303      PMCID: PMC2229995     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  10 in total

1.  Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases.

Authors:  G Kovacs
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

2.  Detection of messenger RNA by in situ hybridization.

Authors:  D Sassoon; N Rosenthal
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

3.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

Authors:  T Shuin; K Kondo; S Torigoe; T Kishida; Y Kubota; M Hosaka; Y Nagashima; H Kitamura; F Latif; B Zbar
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

4.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

5.  Expression of the proto-oncogene int-1 is restricted to specific neural cells in the developing mouse embryo.

Authors:  D G Wilkinson; J A Bailes; A P McMahon
Journal:  Cell       Date:  1987-07-03       Impact factor: 41.582

6.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Authors:  J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

7.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

8.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

9.  Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis.

Authors:  R R Rackley; A M Flenniken; N P Kuriyan; P M Kessler; M H Stoler; B R Williams
Journal:  Cell Growth Differ       Date:  1993-12

10.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas.

Authors:  H Kanno; K Kondo; S Ito; I Yamamoto; S Fujii; S Torigoe; N Sakai; M Hosaka; T Shuin; M Yao
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

  10 in total
  12 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation.

Authors:  Qingzhou Ji; Robert D Burk
Journal:  Biochem Cell Biol       Date:  2008-06       Impact factor: 3.626

Review 3.  The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.

Authors:  Volker H Haase
Journal:  Semin Cell Dev Biol       Date:  2005-04-26       Impact factor: 7.727

Review 4.  Ubiquitin pathway in VHL cancer syndrome.

Authors:  Michael Ohh
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

Review 5.  Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms.

Authors:  T Hsu
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

6.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  V H Haase; J N Glickman; M Socolovsky; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

7.  Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.

Authors:  M Zatyka; C Morrissey; I Kuzmin; M I Lerman; F Latif; F M Richards; E R Maher
Journal:  J Med Genet       Date:  2002-07       Impact factor: 6.318

8.  Wilms' tumor protein induces an epithelial-mesenchymal hybrid differentiation state in clear cell renal cell carcinoma.

Authors:  Valerie B Sampson; Justin M David; Isabel Puig; Pratima U Patil; Antonio García de Herreros; George V Thomas; Ayyappan K Rajasekaran
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

9.  The human plasma membrane peripherome: visualization and analysis of interactions.

Authors:  Katerina C Nastou; Georgios N Tsaousis; Kimon E Kremizas; Zoi I Litou; Stavros J Hamodrakas
Journal:  Biomed Res Int       Date:  2014-06-25       Impact factor: 3.411

10.  Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations.

Authors:  H-C Jennifer Shen; Asha Adem; Kris Ylaya; Arianne Wilson; Mei He; Dominique Lorang; Stephen M Hewitt; Klaus Pechhold; David M Harlan; Irina A Lubensky; Laura S Schmidt; W Marston Linehan; Steven K Libutti
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.